Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials

Okada, Ryuhei; Furusawa, Aki; Vermeer, Daniel W.; Inagaki, Fuyuki; Wakiyama, Hiroaki; Kato, Takuya; Nagaya, Tadanobu; Choyke, Peter L.; Spanos, William C.; Allen, Clint; Kobayashi, Hisataka

doi:10.1016/j.ebiom.2021.103345

Cited by 28 publications

(22 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even in primary tumors, if the initial treatment is only partially successful, repeated endoscopic NIR‐PITs can be performed on the same site at a later time. In mouse models, cancer cell‐targeted NIR‐PIT has been proved to enhance antitumor immune response by releasing various kinds of tumor‐associated antigens (TAAs), 30 , 31 that could help to treat satellite or distant lesions. Repeated NIR‐PITs could work as immune boosters, although such effects are currently investigated.…”

Section: Discussionmentioning

confidence: 99%

Endoscopic near‐infrared photoimmunotherapy in an orthotopic head and neck cancer model

et al. 2021

Self Cite

View full text Add to dashboard Cite

Near‐infrared photoimmunotherapy (NIR‐PIT) is a cell selective cancer therapy that uses an antibody‐photoabsorber (IRDye700DX, IR700) conjugate (APC) and NIR light. NIR‐PIT targeting epidermal growth factor receptor (EGFR) in head and neck cancer (HNC) was conditionally approved in Japan in 2020. APC‐bound tumors can be detected using endoscopic fluorescence imaging, whereas NIR light can be delivered using endoscopic fiber optics. The aims of this study were: (1) to assess the feasibility of endoscopic NIR‐PIT in an orthotopic HNC model using a CD44‐expressing MOC2‐luc cell line; and (2) to evaluate quantitative fluorescence endoscopic imaging prior to and during NIR‐PIT. The results were compared in 3 experimental groups: (1) untreated controls, (2) APC injection without light exposure (APC‐IV), and (3) APC injection followed by NIR light exposure (NIR‐PIT). APC injected groups showed significantly higher fluorescence signals for IR700 compared with the control group prior to therapeutic NIR light exposure, and the fluorescence signal significantly decreased in the NIR‐PIT group after light exposure. After treatment, the NIR‐PIT group showed significantly attenuated bioluminescence compared with the control and the APC‐IV groups. Histology demonstrated diffuse necrotic death of the cancer cells in the NIR‐PIT group alone. In conclusion, endoscopically delivered light combined with quantitative fluorescence imaging can be used to “see and treat” HNC. This method could also be applied to other types of cancer approachable with endoscopy.

show abstract

Section: Discussionmentioning

confidence: 99%

Endoscopic near‐infrared photoimmunotherapy in an orthotopic head and neck cancer model

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, Kim et al 33 cross-linked Ce6 with many targeted molecules, including trastuzumab (1:1), by NHS-activated ester and obtained a new conjugate with better tissue penetration and a 6-fold increase in tumor accumulation. A large number of basic studies 8 , 34 , 35 have shown that NIR-PIT has high targeting ability and few adverse reactions, but the current experiments are mostly at the cellular and animal level ( Table 2 ), and there are relatively few clinical studies ( Table 1 ). Therefore, large-scale clinical trials are needed to confirm the superiority of NIR-PIT in the treatment of malignant tumors.…”

Section: Photoimmunoconjugatementioning

confidence: 99%

“…NIR-PIT can target and treat almost any cell surface antigen in vivo and in vitro such as EGFR, 34 PSMA, 62 PD-L1, 63 CD44, 64 CD133 2 and so on. NIR-PIT directed at CD44 and CD133, 2 which are considered effective in breast cancer and glioblastoma, respectively.…”

Section: Opportunities and Prospectsmentioning

confidence: 99%

“…NIT-PIT’s next step is to take the immune response further. Studies in animals 27 , 34 , 35 with intact immune systems have shown that NIT-PIT targeting of intratumor immunosuppressive cells, such as regulatory T cells, can further selectively enhance the systemic host immunity of tumor cells, resulting in a significant response in distant metastatic tumors. In addition, NIR-PIT can enhance the targeted delivery of nanomaterials to tumors by severely damaging tumor blood vessels and causing super leakage.…”

Section: Opportunities and Prospectsmentioning

confidence: 99%

See 1 more Smart Citation

Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy

Peng

Huang

2022

Cancer Control

View full text Add to dashboard Cite

In recent years, the incidence of cancer has been increasing worldwide. Conventional cancer treatments include surgery, chemotherapy, and radiation, which mostly kill tumor cells at the expense of normal and immune cells. Although immunotherapy is an accurate, rapid, efficient tumor immune treatment, it causes serious adverse reactions, such as cytokine release syndrome (CRS) and neurotoxicity. Therefore, there is an urgent need to develop an effective and nontoxic procedure for immunotherapy. The clinical combination of phototherapy and immunoadjuvant therapy can induce immunogenic cell death and enhance antigen presentation synergy. It also causes a systemic antitumor immune response to manage residual tumors and distant metastases. Photoimmunotherapy (PIT) is a tumor treatment combining phototherapy with immunotherapy based on injecting a conjugate photosensitizer (IR700) and a monoclonal antibody (mAb) to target an expressed antigen on the tumor surface. This combination can enhance the immune response ability, thus having a good effect on the treatment of residual tumor and metastatic cancer. In this review, we summarize the recent progress in photoimmunotherapy, including photoimmunoconjugate (PIC), the activation mechanism of immunogenic cell death (ICD), the combination therapy model, opportunities and prospects. Specifically, we aim to provide a promising clinical therapy for solid tumor clinical transformation.

show abstract

“…Approximately one day after intravenous infusion of an IR700-based APC, NIR light is delivered to the cancer, activating a photochemical reaction that results in highly selective cancer cell killing while leaving normal tissues unaffected [ 4 , 5 , 6 , 7 ]. NIR-PIT has been used to target various cancer-specific proteins, such as epidermal growth factor receptor (EGFR) [ 8 , 9 , 10 , 11 , 12 , 13 ] and human epidermal growth factor receptor-2 (HER2) [ 14 , 15 , 16 , 17 , 18 , 19 ], and both have shown excellent anti-cancer effects. Furthermore, the clinical use of EGFR-targeted NIR-PIT progressed into clinical trials of patients with head and neck squamous cell carcinoma (HNSCC).…”

Section: Introductionmentioning

confidence: 99%

Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers

Fukushima

Türkbey

Pinto

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Near-infrared photoimmunotherapy (NIR-PIT) is a novel molecularly-targeted therapy that selectively kills cancer cells by systemically injecting an antibody-photoabsorber conjugate (APC) that binds to cancer cells, followed by the application of NIR light that drives photochemical transformations of the APC. APCs are synthesized by selecting a monoclonal antibody that binds to a receptor on a cancer cell and conjugating it to IRDye700DX silica-phthalocyanine dye. Approximately 24 h after APC administration, NIR light is delivered to the tumor, resulting in nearly-immediate necrotic cell death of cancer cells while causing no harm to normal tissues. In addition, NIR-PIT induces a strong immunologic effect, activating anti-cancer immunity that can be further boosted when combined with either immune checkpoint inhibitors or immune suppressive cell-targeted (e.g., regulatory T cells) NIR-PIT. Currently, a global phase III study of NIR-PIT in recurrent head and neck squamous cell carcinoma is ongoing. The first APC and NIR laser systems were approved for clinical use in September 2020 in Japan. In the near future, the clinical applications of NIR-PIT will expand to other cancers, including urologic cancers. In this review, we provide an overview of NIR-PIT and its possible applications in urologic cancers.

show abstract

Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials

Cited by 28 publications

References 42 publications

Endoscopic near‐infrared photoimmunotherapy in an orthotopic head and neck cancer model

Endoscopic near‐infrared photoimmunotherapy in an orthotopic head and neck cancer model

Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy

Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers

Contact Info

Product

Resources

About